SUMO4 M55V, located in IDDM5, has been a focus for debate because of its association to type I diabetes (TIDM) in Asians but not in Caucasians. The current study aims to test the significance of M55V association to TIDM in a large cohort of Swedish Caucasians, and to test whether M55V is associated in those carrying human leukocyte antigen (HLA) class II molecules. A total of 673 TIDM patients and 535 age-and sex-matched healthy controls were included in the study. PCR-RFLP was performed to identify the genotype and allele variations. Our data suggest that SUMO4 M55V is not associated with susceptibility to TIDM by itself. When we stratified our patients and controls based on heterozygosity for HLA-DR3/DR4 and SUMO4 genotypes, we found that presence of SUMO4 GG increased further the relative risk conferred by HLA-DR3/DR4 to TIDM, whereas SUMO4 AA decreased the risk. From the current study, we conclude that SUMO4 M55V is associated with TIDM in association with high-risk HLA-DR3 and DR4, but not by itself.
Introduction
Type I diabetes (TIDM) is characterized by autoimmunemediated destruction of insulin secreting b-cells. 1 It is a polygenic disease with over 20 IDDM loci reported to be associated with susceptibility, human leukocyte antigen (HLA) (IDDM1) locus being the main risk factor.
2 Small ubiquitin-related modifier 4 (SUMO4) gene is one such risk factor present on chromosome 6q25, in the IDDM5 region. 3, 4 It encodes the SUMO4 protein, which is suggested to be a post-translational modifier of the inhibitor for nuclear factor-kB (IkB). IkB is a negative regulator of nuclear factor-kB (NFkB). 4 NFkB is a nuclear transcription factor that regulates the expression of genes critical for the regulation of apoptosis, viral replication, inflammation and several autoimmune diseases. 5 A functional, nonsynonymous single nucleotide polymorphism in IDDM5 (rs237025; 163 A-G), causing a methionine-to-valine substitution at codon 55 (M55V) in SUMO4 protein was reported to be associated with TIDM by Guo et al. 3 and Owerbach et al. 4 Studies in several Asian 6À8 and Caucasian 9À12 populations revealed that SUMO4 M55V is associated with TIDM in Asians (Japanese, Korean and Chinese populations) but not in Caucasians. The aim of the current study was to test the M55V association with TIDM in a large homogenous Swedish population and to look at the probable role of high-risk HLA, alleles of MICA and autoantibody status in association with SUMO4 M55V.
Results and discussion
In a large cohort of Swedish patients (n ¼ 673) with TIDM and healthy controls (n ¼ 535), we could not detect any significant association between SUMO4 M55V and TIDM at genotypic (AA, AG and GG); allelic (taking into consideration the presence of two alleles, one on each chromosome, either 2 A or 2 G or an A and a G allele in each subject) or phenotypic (GG þ AG as G phenotype and AA as A phenotype) level ( Table 1 ). The genotypic distribution of AA, AG and GG was compatible with Hardy-Weinberg equilibrium in the control population. SUMO4 M55V was found to be associated with TIDM in the initial report by Guo et al., 3 but later studies in Caucasian populations failed to detect significant association. Cong-Yi et al. 13 suggest that the genetic heterogeneity in the Caucasian population might be the reason for the inconsistency in M55V association studies in Caucasians and this might be due to the presence of multiple TIDM susceptibility genes in IDDM5. Functional evidence of SUMO4 M55V as a TIDM susceptibility gene comes from Guo et al., 3 where they report a significant reduction in the sumoylation function in the V55 variant of the protein, resulting in a 5.5-fold increase in NFkB-dependent transcription. Supporting this initial observation is another recent study by Noso et al., 14 where they report an increased tumor necrosis factor-a secretion in peripheral blood mononuclear cells from type II diabetic patients having GG genotype compared to that of AA. NFkB is a transcription factor, which plays a central regulatory role in various immune-mediated processes such as production of proinflammatory cytokines, inhibition of immune cell apoptosis, development of immune cells, regulation of innate and adaptive immune system and maintenance of immune homeostasis.
HLA-DR3 and DR4 are well-established high-risk alleles for TIDM in northern Europeans. 15 We performed stratification analysis using HLA-DR3/DR4 heterozygotes in patients as a major criterion. We tested the SUMO4 genotype frequencies in this analysis (Table 2 ). In each of these analyses, the patients and controls were stratified into four categories:
and DR4/SUMO4 genotype (AA or AG or GG)).
In this, we found that HLA-DR3/DR4 is positively associated with TIDM in the absence of AA (OR ¼ 6.91, 95% CI ¼ 4.93-9.67, Pp0.0001) or GG (OR ¼ 5.77, 95% CI ¼ 4.22À7.88, Pp0.0001). However if HLA-DR3/DR4 is present along with AA there is a decrease in the relative risk (OR ¼ 3.66, 95% CI ¼ 2.22-6.02, Pp0.0001), whereas in the presence of GG, there is an increase in the relative risk (OR ¼ 8.34, 95% CI ¼ 4.07-17.13, Pp0.0001). In the absence of HLA-DR3/DR4, SUMO4 M55V was negatively associated with TIDM.
Association between SUMO4 M55V and HLA-DR3/ DR4 was examined because of the well-established fact that HLA-DR3/DR4 causes susceptibility to TIDM in Swedes 16, 17 and other European populations. Tsurumaru et al. 18 reported SUMO4 M55V to be positively associated The subjects included in this study were 673 consequently diagnosed new onset TIDM patients and 535 healthy controls in the age group of 0-35 years, age-and sex-matched. 21, 22 Detailed description of study population are described in references. 21, 22 Blood samples were collected and DNA was extracted as part of two major studies (The Swedish Childhood Diabetes Study 21 and The Diabetes Incidence Study (DIS) in Sweden 22 ) previously. DNA samples from only 673 patients (men ¼ 398, women ¼ 275) and 535 healthy controls (men ¼ 274, women ¼ 261) were available for SUMO4 M55V genotyping. The SUMO4 M55V (rs237025) was amplified using PCR sequence specific primer (PCR-SSP) methodology. The following primer sequences were used (Operon, Cologne, Germany): forward primer: 5 0 -TGT GAA CCA CGG GGA TTG TCG-3 0 and reverse primer: 5 0 -TCA GTA GAC ACC TCC CGT AG-3 0 . The PCR was performed as per the protocol published previously. 17 HLA data were available for 627 patients and 488 healthy controls and this was used in the stratification analysis. Statistical analysis: the odds ratio (OR) was calculated as described previously. 23 The difference in genotypes AA, AG and GG; the A and G alleles and phenotypes, between patients and controls, was tested using w 2 test at a confidence interval of 95% and P-values less that 0.05 were considered significant. P-values were corrected for the number of comparisons, wherever appropriate. Hardy-Weinberg equilibrium analysis was performed on the control population.
with TIDM in the absence of high-risk HLA-DR4 in a Japanese population. In our study on Swedish Caucasians, SUMO4 was negatively associated to TIDM in the absence of HLA-DR3/DR4. However, in HLA-DR3/DR4 positives SUMO4 GG increased the risk to TIDM and SUMO4 AA reduced the risk to TIDM. These varying association findings might be a result of different HLA-DR3/DR4 subtypes associated in Japanese and Swedish populations. SUMO4 M55V seems to be conferring additional susceptibility on top of the risk conferred by heterozygous DR3/DR4. MICA allele 5 was previously shown to be positively associated with younger onset TIDM and MICA allele 5.1 positively associated with older onset TIDM. 19 MICA typing was carried out previously. 19 We tested the association of SUMO4 M55V in those carrying MICA allele 5 vs no allele 5 and in those carrying MICA allele 5.1 vs no allele 5.1. SUMO4 M55V was not increased or decreased significantly in either MICA 5 or 5.1 positive TIDM patients (data not shown).
We also tested the association of SUMO4 M55V in those who are positive for autoantibodies to TIDM (GAD65, IA-2 and insulin). SUMO4 M55V was neither decreased nor increased significantly in autoantibodypositive T1DM patients, as compared to autoantibodynegative T1DM patients (data not shown). Comparison of SUMO4 genotypes between autoantibody-positive and autoantibody-negative groups among DR3-and DR4-positive patients did not result in any significant difference (data not shown). Autoantibodies to GAD65, IA-2 and insulin were measured in serum samples collected at the time of diagnosis.
We tested the association of SUMO4 M55V in the following combinations of HLA: DR3/X, DR4/X and DR2/X, the X being non-DR3, non-DR4 and non-DR2, respectively. We could not detect any significant association in this analysis (data not shown).
Guo et al. 20 reported that a major group, out of the 90 potential SUMO4 substrates, consists of antistress proteins, antioxidant enzymes, stress defense proteins and chaperones. Cong-Yi et al. 13 suggest that altered sumoylation of antistress proteins might lead to their degradation by ubiquitylation, resulting in an increased stress causing b-cell death.
In conclusion, SUMO4 GG increases susceptibility to TIDM in HLA-DR3/DR4-positive Swedish type I diabetics and the protective effect of AA is not sufficient to overcome the high risk conferred by HLA DR3/DR4. But SUMO4 M55V by itself is not associated with the disease.
